LIC MF Healthcare Fund

A Sectoral/Thematic Fund scheme from LIC Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF397L01LK4).

NAV ₹38.8358 on 16 November 2026.

Expense ratio

Total expense ratio 1.38% a year for the Direct · Growth plan, as AMFI published it on 29 October 2026: base expense ratio 0.97%, brokerage 0.08%, transaction costs 0.00%, statutory levies including GST 0.33%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year16.9%14.1%-11.0%0.700.73
3 years22.0%14.3%-15.1%1.051.01

Too little NAV history for the 5, 10-year figures.

Category rank: 9th of 13 Direct-Growth funds in Sectoral/Thematic Fund — Pharma, by 3-year Sortino ratio.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 96.2% of the portfolio.

  1. Sun Pharmaceutical Industries Limited — 8.65%
  2. Divi's Laboratories Limited — 7.09%
  3. Apollo Hospitals Enterprise Limited — 6.13%
  4. Torrent Pharmaceuticals Limited — 5.97%
  5. Neuland Laboratories Limited — 5.83%
  6. Aurobindo Pharma Limited — 5.41%
  7. Aster DM Quality Care Limited — 4.64%
  8. Nephrocare Health Services Limited — 4.14%
  9. Fortis Healthcare Limited — 3.87%
  10. Metropolis Healthcare Limited — 3.73%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.